Assessment of Chemotherapy-Induced Organ Damage with Ga-68 Labeled Duramycin.
Acetates
/ chemistry
Animals
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bacteriocins
/ chemistry
Busulfan
/ administration & dosage
Cisplatin
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Gallium Radioisotopes
/ chemistry
Heterocyclic Compounds, 1-Ring
/ chemistry
Kidney
/ diagnostic imaging
Liver
/ diagnostic imaging
Mice
Mice, Inbred BALB C
Neoplasms
/ drug therapy
Peptides
/ chemistry
Positron Emission Tomography Computed Tomography
/ methods
Radiopharmaceuticals
/ chemistry
Tissue Distribution
Apoptosis
Chemotherapy
Duramycin
PET/CT
Toxicity
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
10
8
2019
medline:
3
6
2021
entrez:
10
8
2019
Statut:
ppublish
Résumé
Evaluation of [ Tracer specificity of Ga-68 labeled NODAGA-duramycin was determined in vitro using competitive binding experiments. Organ uptake was analyzed in untreated and doxorubicin, busulfan, and cisplatin-treated mice 2 h after intravenous injection of [ In vitro experiments confirmed specific binding of [ [
Identifiants
pubmed: 31396770
doi: 10.1007/s11307-019-01417-3
pii: 10.1007/s11307-019-01417-3
doi:
Substances chimiques
1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane
0
Acetates
0
Bacteriocins
0
Gallium Radioisotopes
0
Heterocyclic Compounds, 1-Ring
0
Peptides
0
Radiopharmaceuticals
0
duramycin
1391-36-2
Doxorubicin
80168379AG
Gallium-68
98B30EPP5S
Busulfan
G1LN9045DK
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-633Références
Marrer E, Dieterle F (2010) Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 243:167–179
doi: 10.1016/j.taap.2009.12.015
Russell WMS, Burch RL, Hume CW (1959) The principles of humane experimental technique. Methuen, London
Orrenius S, Nicotera P, Zhivotovsky B (2011) Cell death mechanisms and their implications in toxicology. Toxicol Sci 119:3–19
doi: 10.1093/toxsci/kfq268
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FKM, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D’Angiolella V, Dawson TM, Dawson VL, de Laurenzi V, de Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, di Daniele N, di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, el-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G (2018) Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ 25:486–541
doi: 10.1038/s41418-017-0012-4
Zeng W, Wang X, Xu P, Liu G, Eden HS, Chen X (2015) Molecular imaging of apoptosis: from micro to macro. Theranostics 5:559–582
doi: 10.7150/thno.11548
Lederle W, Arns S, Rix A, Gremse F, Doleschel D, Schmaljohann J, Mottaghy FM, Kiessling F, Palmowski M (2011) Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects. EJNMMI Res 1:26
doi: 10.1186/2191-219X-1-26
Ogawa K, Aoki M (2014) Radiolabeled apoptosis imaging agents for early detection of response to therapy. ScientificWorldJournal 2014:732603
doi: 10.1155/2014/732603
Elvas F, Stroobants S, Wyffels L (2017) Phosphatidylethanolamine targeting for cell death imaging in early treatment response evaluation and disease diagnosis. Apoptosis 22:971–987
doi: 10.1007/s10495-017-1384-0
Johnson SE, Ugolkov A, Haney CR, Bondarenko G, Li L, Waters EA, Bergan R, Tran A, O'Halloran TV, Mazar A, Zhao M (2019) Whole-body imaging of cell death provides a systemic, minimally invasive, dynamic, and near-real time indicator for chemotherapeutic drug toxicity. Clin Cancer Res 25:1331–1342
doi: 10.1158/1078-0432.CCR-18-1846
Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21:440–446
doi: 10.1097/FPC.0b013e32833ffb56
Jadapalli JK, Wright GW, Kain V, Sherwani MA, Sonkar R, Yusuf N, Halade GV (2018) Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. Am J Physiol Heart Circ Physiol 315:H1091–H1100
doi: 10.1152/ajpheart.00290.2018
Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302
doi: 10.2165/00002018-200022040-00002
Buggia I, Locatelli F, Regazzi MB, Zecca M (1994) Busulfan. Ann Pharmacother 28:1055–1062
doi: 10.1177/106002809402800911
Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378
doi: 10.1016/j.ejphar.2014.07.025
Banerjee S, Sinha K, Chowdhury S, Sil PC (2018) Unfolding the mechanism of cisplatin induced pathophysiology in spleen and its amelioration by carnosine. Chem Biol Interact 279:159–170
doi: 10.1016/j.cbi.2017.11.019
Adwas AA, Elkhoely AA, Kabel AM, Abdel-Rahman MN, Eissa AA (2016) Anti-cancer and cardioprotective effects of indol-3-carbinol in doxorubicin-treated mice. J Infect Chemother 22:36–43
doi: 10.1016/j.jiac.2015.10.001
Molyneux G, Andrews M, Sones W, York M, Barnett A, Quirk E, Yeung W, Turton J (2011) Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration. Cell Biol Toxicol 27:13–40
doi: 10.1007/s10565-010-9167-1
Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W (2009) Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24:3012–3020
doi: 10.1093/ndt/gfp242
Gremse F, Stark M, Ehling J et al (2016) Imalytics preclinical: interactive analysis of biomedical volume data. Theranostics 6:328–341
doi: 10.7150/thno.13624
Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EAG (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199:221–228
doi: 10.1002/path.1289
Lederle W, Linde N, Heusel J, Bzyl J, Woenne EC, Zwick S, Skobe M, Kiessling F, Fusenig NE, Mueller MM (2010) Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. Am J Pathol 176:981–994
doi: 10.2353/ajpath.2010.080998
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682
doi: 10.1038/nmeth.2019
Rahmim A, Zaidi H (2008) PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 29:193–207
doi: 10.1097/MNM.0b013e3282f3a515
Yao S, Hu K, Tang G, Liang X, du K, Nie D, Jiang S, Zang L (2014) Positron emission tomography imaging of cell death with [
doi: 10.1007/s10495-013-0964-x
Huang B, Fang W, Tian W et al (2012) Experimental study of labeling and biodistribution of
Banerjee SR, Pomper MG (2013) Clinical applications of Gallium-68. Appl Radiat Isot 76:2–13
doi: 10.1016/j.apradiso.2013.01.039
Sanchez-Crespo A (2013) Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot 76:55–62
doi: 10.1016/j.apradiso.2012.06.034
Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ (2016) Preclinical evaluation of [
doi: 10.1186/s13550-016-0227-2
Perse M, Veceric-Haler Z (2018) Cisplatin-induced rodent model of kidney injury: characteristics and challenges. Biomed Res Int 2018:1462802
doi: 10.1155/2018/1462802
Qian Q, Nath KA, Wu Y, Daoud TM, Sethi S (2010) Hemolysis and acute kidney failure. Am J Kidney Dis 56:780–784
doi: 10.1053/j.ajkd.2010.03.025
Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25:201–212
doi: 10.1007/s002590050216
Muller PY, Dieterle F (2009) Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 5:1023–1038
doi: 10.1517/17425250903114174
Altai M, Perols A, Karlstrom AE et al (2012) Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with
doi: 10.1016/j.nucmedbio.2011.10.013
Malmberg J, Perols A, Varasteh Z, Altai M, Braun A, Sandström M, Garske U, Tolmachev V, Orlova A, Eriksson Karlström A (2012) Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with
doi: 10.1007/s00259-011-1992-9
Strand J, Honarvar H, Perols A, Orlova A, Selvaraju RK, Karlström AE, Tolmachev V (2013) Influence of macrocyclic chelators on the targeting properties of
doi: 10.1371/journal.pone.0070028
Grozovsky R, Hoffmeister KM, Falet H (2010) Novel clearance mechanisms of platelets. Curr Opin Hematol 17:585–589
doi: 10.1097/MOH.0b013e32833e7561